Fundz
Funding, M&A and exec moves matched to your market — guaranteed to pay for itself in a year, or we refund it. See terms for full details.See plans →

Leal Therapeutics closes a $30 million Series A extension to advance LTX-001 and LTX-002 clinical trials. The investment round saw participation from Eli Lilly and other existing investors.

PRIVATEAug 17, 2026•about 6 hours ago

Amount Raised

$30 Million

Round Type

Series A

WorcesterBiotechnologyHealth Care

Investors

Phi FundAlexandria Venture InvestmentsChugai Venture FundSv Health Investors' Dementia Discovery FundEuclidean CapitalNewpath PartnersOrbi MedEli Lilly And Company

Description

Leal Therapeutics, a clinical-stage biopharmaceutical company, announced a second close of $30 million in its Series A financing. The funds will be used to advance their LTX-001 through an initial readout of its Phase 1b/2a clinical trial and to progress LTX-002 in ALS trials. The round includes new investor Eli Lilly and several existing investors. The company is committed to revolutionizing neuro-metabolic therapeutics.

Company Information

Company

Leal Therapeutics

Location

Worcester, Massachusetts, United States

About

Leal Therapeutics is a biotechnology company dedicated to developing novel neuro-metabolic therapeutics for patients with high-need central nervous system disorders. Leal was launched in 2021 and is headquartered in Worcester, Mass. Leal's lead programs address the critical intersection between CNS and metabolic disorders. The Leal team has particular expertise in CNS therapeutic development, as well as leveraging human genetics, functional genomics and biomarker analyses to support our mission. Leal has the technological capability to develop and produce small molecule as well as nucleic acid CNS therapeutics at scale.

Don't miss Leal Therapeutics's next move

Get an email the moment Leal Therapeutics raises, hires an exec, or expands — usually minutes after it happens.

One email per event. Unsubscribe anytime.

Related People

Suggested for you
4 contacts
Verified contactsEduardo P., Chief Technology Officer hidden
Predictive Intelligence
Strategic

ML-powered predictions for Leal Therapeutics's next move

Learn about Strategic plan

Funding Insights

Based on industry data
Typical timeline to Series B
Series A companies typically raise their next round in 10-18 months
Monthly burn rate benchmark
47% of Series A startups spend $400k or more per month on operations
VC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.